Drug profile · INN
vilazodone hydrochloride
VIIBRYD
vilazodone hydrochloride (VIIBRYD) is a serotonin transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — vilazodone hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
vilazodone hydrochloride (VIIBRYD) is a serotonin transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin transporter inhibitor
Primary target: 5-hydroxytryptamine receptor 1A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is vilazodone hydrochloride?
vilazodone hydrochloride (VIIBRYD) is a serotonin transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for vilazodone hydrochloride?
VIIBRYD is a marketed brand name for vilazodone hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vilazodone hydrochloride?
vilazodone hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.